Joint statement in support of hepatitis C human challenge studies

Collaborators, Affiliations

Collaborators

other signatories:
Alessio Aghemo, Matthew Akiyama, Mohammad Ali, Harvey Alter, Ralf Bader, Justin R Bailey, Yasemin Balaban, Sayantan Banerjee, Eleanor Barnes, Ralf Bartenschlager, Thomas F Baumert, Marina Berenguer, Ajeet S Bhadoria, Mia Biondi, Paolo Bonanni, Alcino E Bonella, Philip Bruggmann, Julie Bruneau, Rowena A Bull, Maia Butsashvili, Pedro Cahn, Arthur L Caplan, Richard Y Chappell, Francis Chisari, Ray Chung, Graham Cooke, Andrea L Cox, Olav Dalgard, Doan Y Dao, Ara Darzi, Douglas Dieterich, John F Dillon, Gregory J Dore, Joseph S Doyle, Heidi E Drummer, Anna P Durbin, Geoffrey Dusheiko, Jake D Eberts, Nir Eyal, Jordan Feld, Kyle Ferguson, Robert Flisiak, Xavier Forns, Graham R Foster, Steven Foung, Meital Gal-Tanamy, Ed Gane, Adam J Gehring, Jacob George, Marc G Ghany, Daniel T Gilbert, Kimberly Glaze, Kenneth W Goodman, Jason Grebely, Saeed Hamid, Daniel M Haybron, Richard Holton, Louis J Ignarro, Tamika Jackson, Dale Jamieson, Jody Jollimore, Andrew Karaba, Marina Klein, Georg Lauer, Mansun Law, Stanley M Lemon, T Jake Liang, Lin Liu, Volker Lohmann, Lung-Yi Mak, Rui T Marinho, Abigail A Marsh, Lesley Miller, Joshua Morrison, Francesco Negro, Bao-Vuong Nguyen, Kimberly Page, Kerry Paterson, Alisa Pedrana, Thomas Pietschmann, Steven Pinker, Stanley Plotkin, Stuart C Ray, Nancy Reau, William M Remak, Charles M Rice, Ezequiel Ridruejo, Richard J Roberts, Alvin Roth, Nadine Rouphael, Rogier Sanders, Russell Sandvold, Arthur Schafer, Janke Schinkel, Wai-Kay Seto, Naglaa Shoukry, Peter Singer, Sunil Solomon, Chris Somerville, Mark W Sonderup, Mark Sulkowski, Kawsar Talaat, Larry Temkin, Norah Terrault, Chloe Thio, David L Thomas, Alexander J Thompson, Netanel Tzarum, Marc van der Valk, Jennifer Van Gennip, Imam Waked, Alec Walen, Christopher M Walker, Heiner Wedemeyer, Charles Weijer, Dan Wikler, Dominic Wilkinson, Heather Youngs, Man-Fung Yuen, Barry Zack, Ekaterina Zinger

Affiliations

¹ Transfusion Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
² Nuffield Department of Medicine, University of Oxford, Oxford, UK.
³ School of Nursing, York University, Toronto, ON, Canada.
⁴ The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ 1Day Sooner, Washington, DC, 20002, USA, University of Toronto, Toronto, ON, Canada. Electronic address: jake.eberts@1daysooner.org.
⁶ Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, ON, Canada.
⁷ Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁸ 1Day Sooner, Claymont, DE, USA.
⁹ Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY, USA; Departments of Medicine and of Microbiology and Immunology, Université de Montréal, Montréal, QC, Canada.
¹⁰ Laboratory of Liver Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada.
¹¹ Action Hepatitis Canada, Montréal, QC, Canada.
¹² Departments of Philosophy, Medicine, and Epidemiology and Biostatistics, Western University, London, ON, Canada.

PMID: 37742699
PMCID: PMC12931952
DOI: 10.1016/S2468-1253(23)00314-X

Joint statement in support of hepatitis C human challenge studies

Harvey J Alter et al. Lancet Gastroenterol Hepatol. 2023 Nov.

. 2023 Nov;8(11):967-969.

doi: 10.1016/S2468-1253(23)00314-X. Epub 2023 Sep 21.

Authors

Collaborators

other signatories:
Alessio Aghemo, Matthew Akiyama, Mohammad Ali, Harvey Alter, Ralf Bader, Justin R Bailey, Yasemin Balaban, Sayantan Banerjee, Eleanor Barnes, Ralf Bartenschlager, Thomas F Baumert, Marina Berenguer, Ajeet S Bhadoria, Mia Biondi, Paolo Bonanni, Alcino E Bonella, Philip Bruggmann, Julie Bruneau, Rowena A Bull, Maia Butsashvili, Pedro Cahn, Arthur L Caplan, Richard Y Chappell, Francis Chisari, Ray Chung, Graham Cooke, Andrea L Cox, Olav Dalgard, Doan Y Dao, Ara Darzi, Douglas Dieterich, John F Dillon, Gregory J Dore, Joseph S Doyle, Heidi E Drummer, Anna P Durbin, Geoffrey Dusheiko, Jake D Eberts, Nir Eyal, Jordan Feld, Kyle Ferguson, Robert Flisiak, Xavier Forns, Graham R Foster, Steven Foung, Meital Gal-Tanamy, Ed Gane, Adam J Gehring, Jacob George, Marc G Ghany, Daniel T Gilbert, Kimberly Glaze, Kenneth W Goodman, Jason Grebely, Saeed Hamid, Daniel M Haybron, Richard Holton, Louis J Ignarro, Tamika Jackson, Dale Jamieson, Jody Jollimore, Andrew Karaba, Marina Klein, Georg Lauer, Mansun Law, Stanley M Lemon, T Jake Liang, Lin Liu, Volker Lohmann, Lung-Yi Mak, Rui T Marinho, Abigail A Marsh, Lesley Miller, Joshua Morrison, Francesco Negro, Bao-Vuong Nguyen, Kimberly Page, Kerry Paterson, Alisa Pedrana, Thomas Pietschmann, Steven Pinker, Stanley Plotkin, Stuart C Ray, Nancy Reau, William M Remak, Charles M Rice, Ezequiel Ridruejo, Richard J Roberts, Alvin Roth, Nadine Rouphael, Rogier Sanders, Russell Sandvold, Arthur Schafer, Janke Schinkel, Wai-Kay Seto, Naglaa Shoukry, Peter Singer, Sunil Solomon, Chris Somerville, Mark W Sonderup, Mark Sulkowski, Kawsar Talaat, Larry Temkin, Norah Terrault, Chloe Thio, David L Thomas, Alexander J Thompson, Netanel Tzarum, Marc van der Valk, Jennifer Van Gennip, Imam Waked, Alec Walen, Christopher M Walker, Heiner Wedemeyer, Charles Weijer, Dan Wikler, Dominic Wilkinson, Heather Youngs, Man-Fung Yuen, Barry Zack, Ekaterina Zinger

Affiliations

¹ Transfusion Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
² Nuffield Department of Medicine, University of Oxford, Oxford, UK.
³ School of Nursing, York University, Toronto, ON, Canada.
⁴ The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ 1Day Sooner, Washington, DC, 20002, USA, University of Toronto, Toronto, ON, Canada. Electronic address: jake.eberts@1daysooner.org.
⁶ Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, ON, Canada.
⁷ Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁸ 1Day Sooner, Claymont, DE, USA.
⁹ Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY, USA; Departments of Medicine and of Microbiology and Immunology, Université de Montréal, Montréal, QC, Canada.
¹⁰ Laboratory of Liver Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montréal, QC, Canada.
¹¹ Action Hepatitis Canada, Montréal, QC, Canada.
¹² Departments of Philosophy, Medicine, and Epidemiology and Biostatistics, Western University, London, ON, Canada.

PMID: 37742699
PMCID: PMC12931952
DOI: 10.1016/S2468-1253(23)00314-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

The views expressed above are those of the individual signatories, and do not necessarily represent an endorsement by their institutions. JDE and JM are employees of 1Day Sooner, which organised this letter and has received funding from Open Philanthropy in support of its hepatitis C-related work. MJB has received research grants from AbbVie, Gilead, and Cepheid. JJF has received research grants from AbbVie and Gilead, and consulting payments from AbbVie, Gilead, Arbutus, GSK, Roche, Vir, and Janssen. JVG's organisation has received payments from AbbVie, Gilead, and Cepheid, and JVG has participated in data safety monitoring boards or advisory boards for AbbVie and Gilead. ALC and DLT are professors at The Johns Hopkins University, which has received funding from the US National Institutes of Health (NIH; 5U19AI159822-03) for hepatitis C vaccine development; ALC is a principal investigator on several subprojects. EB is a principal investigator on another subproject under the same NIH grant. DLT owns stock in Excision Bio, has received consulting payments from Excision Bio and Everys Bio and payment from Merck for participation on an advisory board. CW has received consulting fees from Eli Lilly & Company, Cardialen, and Research Triangle Institute International. HJA, TJL, and NHS declared no competing interests.

References

1. The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022; 7: 396–415. - PubMed
1. Fleurence RL, Collins FS. A national hepatitis C elimination program in the United States: a historic opportunity. JAMA 2023; 329: 1251–52. - PubMed
1. Page K, Melia MT, Veenhuis RT, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med 2021; 384: 541–49. - PMC - PubMed
1. Global Burden of Disease Collaborative Network. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet 2018; 392: 1745–50. - PMC - PubMed
1. Liang TJ, Feld JJ, Cox AL, Rice CM. Controlled human infection model—fast track to HCV vaccine? N Engl J Med 2021; 385: 1235–40. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Elsevier Science
- PubMed Central
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Joint statement in support of hepatitis C human challenge studies

Collaborators

Affiliations

Joint statement in support of hepatitis C human challenge studies

Authors

Collaborators

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical